Global Encephalopathy Treatment Market 2019-2023 | Emergence of Novel Treatment Targets for Encephalopathy to Boost demand | Technavio
LONDON--(BUSINESS WIRE)--Nov 8, 2018--The global encephalopathy treatment market 2019-2023 is expected to post a CAGR of close to 5% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181108005340/en/
Technavio predicts the global encephalopathy treatment market to post a CAGR of close to 5% by 2023. (Graphic: Business Wire)
A key factor driving the growth of the market is the rise in the number of initiatives to increase awareness about disease management. Initiatives to increase the number of programs for fostering the awareness about the management of encephalopathy is on the rise. For instance, the Salix’s Hepatic Encephalopathy Living Program (H.E.L.P), a support program for healthcare providers and patients, is directed at the effective management of hepatic encephalopathy. The program aims at providing co-pay assistance, educational material for hepatic encephalopathy, and treatment adherence support.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the emergence of novel treatment targets for encephalopathy as one of the key emerging trends in the global encephalopathy treatment market:
Global encephalopathy treatment market: Emergence of novel treatment targets for encephalopathy
Rifaximin and Lactulose are the only two drugs approved for the treatment of hepatic encephalopathy and Aldesleukin and Rituximab are the only two drugs approved for the treatment of Hashimoto’s encephalitis. No other drugs are available for the treatment of other types of encephalopathy such as infectious encephalopathy and diabetic encephalopathy.
“Another drug, OCR-002 reduces the ammonia level in patients. OCR-OO2 effectively binds ammonia, which is a major healing mechanism in hepatic encephalopathy. L-ornithine and L-aspartate are two agents under evaluation for use in the prevention of hepatic encephalopathy in individuals diagnosed with cirrhosis.” says a senior analyst at Technavio for research on human-machine interface.
Global encephalopathy treatment market: Segmentation analysis
This market research report segments the global encephalopathy treatment market by type (hepatic encephalopathy, diabetic encephalopathy, infectious encephalopathy, and others) and geographical regions (APAC, EMEA, and the Americas).
The hepatic encephalopathy segment accounted for almost 52% of the market share in 2018. This segment is expected to dominate during the forecast period owing to its cost-effectiveness.
The Americas led the market in 2018 with a market share of close to 47%, followed by EMEA and APAC respectively. Due to the high incidence of these indications in the region, the encephalopathy treatment market in the Americas is expected to continue to dominate the market during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181108005340/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH DIABETES
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 11/08/2018 10:01 AM/DISC: 11/08/2018 10:01 AM